Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vir Biotechnology Q2 2024 Adj EPS $(1.02) Misses $(0.90) Estimate, Sales $3.10M Miss $7.50M Estimate

Author: Benzinga Newsdesk | August 01, 2024 04:21pm
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.90) by 13.33 percent. The company reported quarterly sales of $3.10 million which missed the analyst consensus estimate of $7.50 million by 58.65 percent. This is a 18.36 percent decrease over sales of $3.80 million the same period last year.

Posted In: VIR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist